Amy S. Clark, MD, MSCE
Jill and Alan Miller Associate Professor in Breast Cancer Excellence
Department: Medicine
Contact information
Perelman Center for Advance Medicine
10th Floor, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA, 19104
Philadelphia, PA 19104
10th Floor, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA, 19104
Philadelphia, PA 19104
Education:
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent linkBS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Description of Clinical Expertise
I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.Description of Research Expertise
My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.Selected Publications
Ana C. Garrido-Castro1, Tianyu Li2, Se Eun Kim2, Jennifer Desrosiers1, Rita Nanda3, Yara Abdou4, Amy S. Clark5, Ruth Sacks6, Thomas O’Connor1, Natalie Sinclair1, Steve Lo7, Grace Audahl1, Eileen Wrabel1, Tess O’Meara1, Tanya E. Keenan1,8*, Nancy U. Lin1, Harold J. Burstein1, Elizabeth A. Mittendorf1, Nabihah Tayob2, Sara M. Tolaney1 : SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative metastatic breast cancer ESMO Open 11(Supplement 4): 107447, May 2026 Notes: Abstract Presented at 2026 ESMO Breast Cancer Annual CongressShen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.: Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes. Stat Med 45(8-9), Apr 2026.
Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES.: CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy J Natl Compr Canc Netw. 24(3.5): CLO26-104, Mar 2026.
Phun J, Clark A, Zhang J, Nayak, A.: Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals. Laboratory Investigation 106(3): 104474, Mar 2026.
Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. : The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy Cancer Cell 44(3): 449-454, Mar 2026.
J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team: Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study Clin Cancer Res 32(4 suppl): PS4-07-15, Feb 2026 Notes: Poster Abstract- 2025 San Antonio Breast Cancer Symposium, San Antonio, TX
R. Jaber Chehayeb; P. Coutifaris; F. White; J. Heintz; S. L. Jacob; J. Q. Zhang; O. M. Fayanju; E. S. Lebrow; N. Taunk; K. Lee; H. Knollman; I. Makhlin; A. Clark; R. Jankowitz; A. Nayak; S. Domchek; A. DeMichele; P. D. Shah : Factors associated with pCR and distant recurrence in patients with early-stage TNBC treated with KN522. Clin Cancer Res 32(4 Suppl): PS4-07-07, Feb 2026 Notes: Poster Session Abstract: 2025 San Antonio Texas Breast Cancer Symposium, San Antonio, TX
Pohlmann PR, Rugo HS, Yau C, Yee D, Chien AJ, Williams NO, Wallace AM, Boughey JC, Vaklavas C, Arora M, Borges V, Clark AS, Omene C, Isaacs C, Stringer-Reasor E, Nanda R, Falkson C, Albain KS, Chan N, Roussos Torres ET, Rozenblit M, Tseng J, Bommakanti S, Nangia C, Brown-Swigart L, Hirst GL, Pasricha N, Kretzer CH, Perlmutter J, Borowsky A, Symmans WF, van 't Veer LJ, Hylton N, Esserman LJ: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788 in the neoadjuvant setting: Results from the I-SPY2.2 trial. Clin Cancer Research 32(4 Suppl): PD10-02, Feb 2026 Notes: Poster Presentation- 2025 San Antonio Breast Cancer Symposium, San Antonio, TX
Chien, J., Mukhtar, R.A., Yau, C., Elias, A. D., Wallace, A. M., Chan, N., Omene, C., Tseng, J., Trivedi, M. S., Stringer-Reasor, E., Yee, D., Clark, A. S., Thomas, A., Han, H., Arora, M., Nangia, C., Albain, K., Falkson, C., Isaacs, C., Zimmer, A., Rozenblit, M., van 't Veer, L., Swigart, L. B., Hirst, G. L., Symmans, W. F., Borowsky, A. D., Onishi, N., Hylton, N., Alkhafaji, S., Giridhar, K. V., Vaklavas, C., Wei, M., Goetz, M. P., Chen, N., Olopade, O., Huppert, L., Wu, C., Esserman, L. J. : I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients (pts) with HR+ HER2- Stage 2/3 breast cancer (BC). Clin Cancer Res 32(4 Suppl): PD10-02, Feb 2026 Notes: Poster Presentation- 2025 San Antonio Breast Cancer Symposium, San Antonio, TX.
Jung W, Ko K, Smith AM, Huang A, Xia C, Martei YM, Narayan VK, Clark AS, Lefebvre B, McDermott K, Koropeckyj-Cox D, Fasan O, Hutsell A, Daniels A, Englefield V, Leger KJ, Getz KD, Narayan HK, Marshall JD, Powell-Wiley TM, Yancy CW, Ky B. : Air Pollution and Cardiac Remodeling and Function in Patients With Breast Cancer JAMA Netw Open 9(1), Jan 2026.